$YCBD

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

cbdMD, Inc. (YCBD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women ’ s Beauty, Weight Loss and Longevity Wellness Agreement will add iconic supplement brands to cbdMD ’ s growing multi-brand consumer wellness platf

cbdMD, Inc. (NYSE American: YCBD) reported Q3 FY2026 results ended June 30, 2026. Revenue rose 20% year over year to $5.6 million, driven by 61% higher wholesale net sales and a full quarter contribution from Bluebird Botanicals. Oasis distribution expanded. Loss from operations was about $1.13 million. The company cited federal hemp legislation timing and expected monthly cost savings up to $150,000.

cbdMD, Inc. (NYSE American: YCBD) said a Senate continuing resolution released Aug. 2 would delay federal hemp restrictions on most hemp products from Nov. 12 to Dec. 11, preserving access to naturally derived full-spectrum CBD. The company said the language is not yet law and would need final House and Senate approval and presidential signature.

cbdMD, Inc. (NYSE American: YCBD) said it supports the bipartisan Lawful Hemp Protection Act by Reps. Andy Barr and Angie Craig, which would set a long-term federal regulatory framework for hemp-derived products. The company also backed an administration call to update the federal hemp definition before a Nov. 12, 2026 narrowing deadline under FY2026 appropriations.

cbdMD, Inc. (NYSE American: YCBD) said its Bluebird Botanicals brand partnered with Denver Audubon to support bird conservation in Colorado. Under the “Buy Bluebird, Save Bluebirds” campaign, Bluebird will contribute 1% of profits from Bluebird product sales over three months this summer. cbdMD said the move follows its investment in Bluebird after acquiring the brand.

The article discusses cbdMD Inc (YCBD) and claims the company’s management is optimistic after its March quarter results. It says management cut $100 million in waste to focus on higher-margin growth despite a reported revenue decline. It also promotes an Insider Monkey newsletter, citing past returns and offering a “$3” stock with “400% upside” claims.

cbdMD has extended and restructured the lease for its Charlotte, North Carolina headquarters and warehouse facilities, securing a new expiration date of November 30, 2031. The company will reduce its leased footprint to 40,000 square feet, which management believes is sufficient for current and future operations. This amendment is expected to result in an annual gross rent expense reduction of approximately $450,000 and a net rent expense reduction of $100,000 to $120,000 after accounting for sublet income.

cbdMD (YCBD) reported mixed Q2 2026 results, with EPS missing estimates by 60.0% at -$0.08, despite revenue of $5.6M beating expectations by 6.6% and growing 19% year-over-year. The company faces profitability challenges, evidenced by a deteriorating net margin of -14.2% and increased reliance on lower-margin wholesale channels, as well as organic growth concerns for its core CBD business. Investors will be watching for signs of operating leverage, stabilization of the DTC channel, and management of cash burn.

cbdMD (YCBD) reported a mixed Q2 2026, with revenue exceeding expectations but a wider-than-anticipated loss per share. The company posted a loss of $0.08 per share against an estimated $0.05 loss, while revenue hit $5.6M, beating the $5.3M estimate. Despite the quarterly loss, cbdMD showed significant year-over-year improvement, with EPS narrowing by 95.8% and revenue growing by 19.0%.